Drug Discovery
Pets have become integral members of modern families, and their health is a growing concern. Pet drugs have emerged as a significant focus within drug development. However, pets (particularly cats and dogs) exhibit substantial differences from humans in terms of physiology, metabolic pathways, and disease profiles. This presents unique challenges for pet drug development, including species-specific characteristics, limited available models, and specialized regulatory pathways. The development of safe, effective, and convenient drugs is crucial for safeguarding pet health.
Protheragen PawDiscover is a company specializing in pet disease research and the development of drugs. With a team of experienced researchers and advanced R&D platforms, we offer one-stop drug discovery services, whether for common ailments like arthritis and skin diseases, or complex challenges such as cancer and rare genetic disorders. If you have any needs, please do not hesitate to contact us.
Our Services
Using advanced technologies, including high-throughput screening, computer-aided design, and genetic engineering, Protheragen PawDiscover provides comprehensive pet drug discovery services, covering a variety of drug types such as small-molecule chemicals and large-molecule biologics. Our services span the entire drug discovery process, including target validation, lead compound screening, pharmacodynamic evaluation, pharmacokinetic studies, and safety assessment.
Small Molecule Drug Discovery
Antibody Drug Discovery
Peptide Drug Discovery
Recombinant Protein Discovery
Gene Therapy Drug Discovery
Cell Therapy Drug Discovery
Vaccine Discovery
Other Drug Discovery
Drug Discovery Workflow
Our Platforms
AI-Powered Drug Design Platform
Using machine learning and deep learning algorithms, this platform mines vast amounts of chemical and biological data to accurately predict compound-target interactions and optimize drug physicochemical properties, thereby accelerating lead compound discovery and optimization.
High-Throughput Screening Platform
Equipped with advanced automated liquid handling systems and high-speed detection instruments, this platform enables rapid activity and toxicity screening of tens of thousands to hundreds of thousands of compounds within a single day, efficiently identifying promising hit compounds for development.
Hybridoma Technology Platform
Through the workflow of animal immunization, cell fusion, and monoclonal screening, this platform develops highly specific therapeutic antibodies for pets. It preserves the advantage of native heavy-light chain pairing, making it suitable for complex antigen targets and accelerating monoclonal antibody candidate discovery.
Synthetic Biology Platform
Leveraging gene editing and modular components (promoters, RBS), this platform optimizes antigen expression for pet pathogens. It engineers bacterial strains/cell lines to enhance vaccine protein yield, empowering efficient subunit vaccine development.
Green Chemistry Platform
Applying flow chemistry, catalytic conversion, and solvent substitution technologies, this platform reduces synthetic steps and waste generation. It ensures small-molecule drug R&D aligns with sustainable principles, lowers environmental footprint, and supports green process development.
Pet Disease Model Platform
We have established multiple disease models for canines and felines that mimic real pathological environments. These enable precise evaluation of drug efficacy and safety, ensuring accurate prediction of pet responses to medication.
Therapeutic Areas
Cardiovascular Disease
Oncology
Infectious Disease
Ophthalmological Disease
Neurological Disease
Dermatological and Allergic Diseases
Respiratory Disease
Other Diseases
Why Choose Us?
Interdisciplinary Expert Team
Our core team is composed of experts from veterinary medicine, medicinal chemistry, molecular biology, computational biology, and other fields. This unique interdisciplinary background enables us to deeply understand the species-specificity of pet diseases, ensuring we deliver high-quality services to our clients.
Proprietary Efficacy Evaluation System
We have established a variety of pet disease models. This ensures our R&D strategies are closely aligned with the actual needs of pets from the outset, significantly increasing the success rate of translation from laboratory research to clinical application and avoiding R&D failures due to species differences.
Advanced Technology Platforms
We possess cutting-edge platforms including AI-assisted drug design, high-throughput screening, hybridoma technology, and pet disease models. These robust technological platforms ensure we can tackle complex R&D challenges, provide optimal drug discovery solutions for pets, and accelerate the drug development process.
Flexible Customization & High-Efficiency Responsiveness
We reject a "one-size-fits-all" approach. We tailor R&D strategies based on the specific goals, budget, and timeline of each project. Each project is supported by an experienced dedicated project manager and scientific team, ensuring smooth communication, rapid responsiveness, and transparent, efficient project execution.
